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Objectives. This study sought to determine whether successful
recanalization of an occluded vein graft is associated with im-
provement in long-term clinical outcome.
Background. Coronary angioplasty of occluded vein grafts is
associated with a lower initial success rate and a higher compli-
cation rate than angioplasty of vein grafts with subtotal stenoses
and native coronary arteries. Whether successful angioplasty
improves clinical outcome is unknown.
Methods. We analyzed 77 consecutive patients who underwent
angioplasty of an occluded saphenous vein coronary artery bypass
graft between August 1983 and June 1994. Patients with a
myocardial infarction in the previous 24 h were excluded from the
study.
Results. The mean age of the study cohort was 65 years; the
mean (SD) age of the treated grafts was 7.5  3.9 years. As an
adjunct to balloon angioplasty, stents were used in 9% of proce-
dures, laser in 30%, and atherectomy in 16%, and thrombolytic
therapy was administered in 23% of patients. The angioplasty
success rate was 71%. Major complications within 30 days of the
procedure included death in 5.2% of patients, Q wave myocardial
infarction in 1.3% and repeat bypass surgery in 7.8%; these events
occurred with similar frequency in patients in whom angiographic
success was and was not achieved. Kaplan-Meier analysis com-
paring patients in whom angioplasty was successful (n  55) and
not successful (n  22) revealed no differences in survival or
occurrence of myocardial infarction or recurrent severe angina
between the two groups in the 3 years after the procedure.
Univariate analysis identiﬁed the age of the graft and use of newer
interventional devices as predictors of death or myocardial infarc-
tion during this time period; procedural success was not associ-
ated with freedom from these adverse events after adjusting for
these variables.
Conclusions. Angioplasty of occluded vein grafts is associated
with a low initial success rate and a high complication rate.
Successful angioplasty does not appear to reduce the occurrence
of adverse events in the 3 years after the procedure.
(J Am Coll Cardiol 1996;28:1732–7)
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The long-term beneﬁts of coronary artery bypass surgery are
limited by the frequency with which vein grafts develop ath-
erosclerosis. More than 50% of vein grafts have stenoses
70% at 5 years (1). The frequency with which percutaneous
transluminal coronary angioplasty is performed in patients
with previous coronary artery bypass surgery is increasing each
year (2). In view of the high morbidity and mortality associated
with repeat bypass surgery (3), cardiologists have attempted to
avoid repeat surgery by using percutaneous revascularization
strategies when possible. However, the results of percutaneous
treatment of vein graft disease have been disappointing. The
second Coronary Angioplasty Versus Excisional Atherectomy
Trial (CAVEAT II) (4), in which balloon angioplasty and
directional atherectomy were compared in the treatment of
stenotic vein grafts, conﬁrmed the results of previous studies
indicating a lower success rate and a higher complication rate
with both balloon angioplasty and directional atherectomy of
vein grafts than has been reported for the native coronary
arteries (5).
The results of angioplasty of occluded vein grafts have been
even less favorable (6–9). Success rates ranging from 27% to
73% have led some cardiologists to suggest that angioplasty of
occluded vein grafts “is a challenge that should be resisted”
(6–9). Nevertheless, reports of improved success rates with
new interventional devices or prolonged infusions of thrombo-
lytic agents have provided impetus for continuing to attempt
these difﬁcult procedures (10,11). However, whether patients
with occluded vein grafts in whom angioplasty is successful
derive long-term clinical beneﬁt from the procedure remains
unclear. Therefore, we performed the present study to deter-
mine the frequency of success and complications in patients in
whom percutaneous revascularization of an occluded saphe-
nous vein bypass graft was attempted and to determine
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whether adverse cardiovascular events were reduced after the
procedure in patients in whom the procedure was successful.
Methods
Patients. We performed a retrospective analysis of the
cardiac catheterization laboratory databank and reviewed all
coronary interventional procedures performed at our institu-
tion between October 1979 and September 1994. Seventy-
seven patients who had undergone attempted percutaneous
revascularization of an occluded saphenous vein bypass graft,
with no acute myocardial infarction in the 24 h before the
procedure, were identiﬁed. These 77 patients, who were
treated between August 1983 and June 1994, form the study
cohort. This study was approved by the Institutional Review
Board of the Mayo Clinic.
Deﬁnitions. Angiographic success was achieved when the
ﬁnal residual lumen diameter stenosis in the treated vein graft
was 50%. Severity of coronary artery stenoses was deter-
mined by hand-held calipers or visual assessment by two
observers using orthogonal views. Angina was classiﬁed ac-
cording to the Canadian Cardiovascular Society classiﬁcation
scheme. Severe angina was deﬁned as class III or IV angina.
Single-vessel disease was considered to be present when a single
native coronary artery had a 70% diameter stenosis that was
either not grafted or was supplied by a graft with a 70%
diameter stenosis. Two- and three-vessel disease were consid-
ered to be present when a70% diameter stenosis was present
in an ungrafted coronary artery or vein graft and a second or
third native coronary artery had a 50% diameter stenosis or
were supplied by bypass grafts in which a 50% diameter
stenosis was present. Complete revascularization was consid-
ered to have been achieved when there was no remaining
diameter stenosis 70% in a bypass graft or ungrafted coro-
nary artery. Myocardial infarction during the follow-up period
was considered to have occurred when two of the following
three criteria were met: 1) prolonged chest pain thought to be
the result of myocardial ischemia by the patient’s physician; 2)
serum creatine kinase (CK) elevation to two times normal
levels or elevated MB isoenzyme; or 3) development of new Q
waves or signiﬁcant ST-T wave changes on the electrocardio-
gram (ECG).
Left ventricular ejection fraction was calculated using a
modiﬁed Simpson’s rule from ventriculography performed in a
30 right anterior oblique projection.
Follow-up. Patients were contacted 6 and 12 months after
the procedure and at yearly intervals thereafter and were
interviewed by telephone. The case records of all patients
followed up at this institution were examined. Documentation
of adverse events that occurred at other institutions during the
follow-up period was sought from the attending physicians at
those institutions. Follow-up angiography was generally only
performed for clinical indications at the discretion of the
attending physician, such as the recurrence of severe angina or
an early positive functional test.
Major end points during follow-up were the occurrence of
death, myocardial infarction (Q wave or non-Q wave) and
severe (Canadian Cardiovascular Society class III or IV)
angina. The frequency of repeat coronary angioplasty and
coronary artery bypass surgery were also analyzed.
Statistical analysis. Results are presented as either mean
value  SD, medians (25th and 75th percentiles [in tables]) or
as a percent. Kaplan-Meier curves using the endpoints of
death, myocardial infarction, recurrent severe angina and the
need for repeat coronary artery bypass surgery or coronary
angioplasty were computed for patients in whom angiographic
success was and was not achieved; the log-rank statistic was
used to compare the two groups. The effect of angiographic
success was evaluated using a Cox proportional hazards model
after adjusting for other signiﬁcant variables. The Cox models
were developed using the forward-selection process. The vari-
ables evaluated in the model process were age, gender, graft
age, multivessel disease, medication prescribed at the time of
discharge (including beta-adrenergic blocking agents, calcium
channel blocking agents, nitrates, aspirin and Coumadin),
myocardial infarction in the 2 to 7 preceding days and use of
interventional devices other than balloon angioplasty cathe-
ters. Differences were considered to be statistically signiﬁcant
at p  0.05.
Results
Baseline characteristics. The baseline clinical characteris-
tics of the 77 study patients are shown in Table 1. The mean
age of the study cohort was 65  9 years, and 87% were male.
A previous myocardial infarction had occurred in 79% of
patients; 29% had had a myocardial infarction in the preceding
2 to 7 days. Two-vessel disease was present in 44% of patients
and three-vessel disease in 29%. The occluded bypass graft was
to the left anterior descending coronary artery in 39% of
patients, the left circumﬂex coronary artery in 31% and the
right coronary artery in 29%. The mean age of the occluded
vein graft was 7.7  3.8 years.
Procedural characteristics. Adjunctive device use changed
throughout the study period as new devices became available
and as knowledge and experience with them increased. Balloon
angioplasty alone was used in 52% of the procedures. Intra-
coronary or biliary stents were used in 9% of patients. Excimer
laser was used in 30% of patients. The transluminal extraction
catheter was used in 10% of cases; directional atherectomy was
Abbreviations and Acronyms
CAVEAT II  second Coronary Angioplasty Versus Excisional
Atherectomy Trial
CI  conﬁdence interval
CK  creatine kinase
ECG  electrocardiogram
RR  relative risk
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used in 6%. Intracoronary thrombolytic therapy was adminis-
tered during the procedure in 23% of the procedures.
During the angioplasty procedure, a coronary artery or
subtotal vein graft stenosis was dilated in 30% of patients. The
mean number of coronary artery segments or vein grafts
dilated was 1.6. Complete revascularization was achieved in
40% of patients.
Comparison of patients in whom angiographic success was
and was not achieved. Angiographic success was achieved in
55 (71%) of 77 patients. When these 55 patients in whom
angiographic success was achieved (Group 1) were compared
with the 22 patients in whom it was not achieved (Group 2),
there were no differences in the baseline clinical and angio-
graphic characteristics between the two groups, except that the
age of the treated graft was slightly greater in Group 1 than
Group 2 patients (8.1  3.7 vs. 6.0  4.0 years, p  0.04).
Angiographic results and immediate clinical outcome. The
mean postprocedural lumen diameter stenosis in Group 1
patients was 26  13%. Among Group 2 patients, the mean
postprocedural lumen diameter stenosis was 72  31%; the
vein graft remained completely occluded in 14 patients, and 11
patients had “partial success,” with stenoses ranging from 50%
to 90%.
A major complication (death, Q wave myocardial infarction
or repeat coronary artery bypass surgery) occurred within 30
days of the procedure in 10 patients (13.0%) (Table 2). There
were no differences in the frequency of these major adverse
cardiovascular events or in the frequency of less severe adverse
events (angiographically evident distal embolization or eleva-
tion of CK levels) between patients in whom angiographic
success was and was not achieved. There was also no difference
in the frequency of a major complication between patients in
whom a myocardial infarction had occurred in the 2 to 7 days
before the procedure and the remaining patients (death 9.1%
vs. 3.6%; Q wave myocardial infarction 4.5% vs. 0, bypass
surgery 9.1% vs. 7.3%; any of these complications occurred in
18.2% vs. 10.9%, p  NS for all comparisons). All complica-
tions occurred during the hospital period in which the angio-
plasty procedure was performed.
Medications at time of discharge. Among patients with
and without angiographic success, medications prescribed at
the time of discharge included, respectively, beta-blockers in
53% and 45% (p  0.55); oral or topical nitrates in 79% and
70% (p  0.41); calcium channel blockers in 64% and 68%
(p  0.72); aspirin in 69% and 80% (p  0.38); and Coumadin
in 77% and 35% (p  0.001).
Table 1. Baseline Clinical and Angiographic Characteristics of 77 Patients Who Underwent
Angioplasty of an Occluded Saphenous Vein Bypass Graft
Characteristic
Entire Study Cohort
(n  77)
Group 1
(n  55)
Group 2
(n  22) p Value
No. of procedures 77 (100) 55 (71) 22 (29)
Age (yr)
Mean  SD 65  9 65  9 65  9 0.88
Median (25th, 75th percentiles) 66 (57, 71) 66 (57, 70) 66 (57, 72)
Range 45–85 45–85 49–79
Male 67 (87) 49 (89) 18 (82) 0.39
CCS angina class III/IV 61 (79) 42 (76) 19 (86) 0.59
Diabetes mellitus 19 (25) 11 (20) 8 (36) 0.13
Hx of hypertension 42 (55) 29 (53) 13 (59) 0.61
Hx of hypercholesterolemia 40 (52) 33 (60) 7 (32) 0.08
Hx of smoking 58 (75) 44 (80) 14 (64) 0.13
Current smoker 8 (10) 5 (9) 3 (14) 0.34
Hx of heart failure 20 (26) 15 (27) 5 (23) 0.27
Hx of MI 61 (79) 42 (76) 19 (86) 0.59
MI within previous 2–7 days 22 (29) 15 (27) 7 (32) 0.93
2-VD 34 (44) 23 (42) 11 (50) 0.51
3-VD 22 (29) 16 (29) 6 (27) 0.87
LVEF (%)
Mean  SD (n  28) 52  17 54  15 47  23 0.40
Median (25th, 75th percentiles) 55 (41, 66) 55 (39, 66) 54 (48, 64)
Native coronary artery grafted:
LAD 39 (39) 29 (42) 10 (33) 0.42
LCx 31 (31) 19 (28) 12 (40) 0.22
RCA 29 (29) 21 (30) 8 (27) 0.71
Graft age (yr)
Mean  SD 7.7  3.8 8.5  3.5 6.0  4.1 0.002
Median (25th, 75th percentiles) 8 (5, 10) 9 (6, 11) 6 (3, 10)
Data presented are number (%) of patients, unless otherwise indicated. CCS  Canadian Cardiovascular Society;
Group 1  angiographic success achieved; Group 2  angiographic success not achieved; Hx  history; LAD  left
anterior descending coronary artery; LCx  left circumﬂex artery; MI  myocardial infarction; RCA  right coronary
artery; VD  vessel disease.
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Adverse events during follow-up. The 77 patients in whom
angioplasty was attempted were followed up for a median of
1.8 years (mean 2.0  1.9). Kaplan-Meier curves of the
occurrence of adverse events in the 3 years after the procedure
in patients in whom angiographic success was (n 55) and was
not achieved (n  22) are displayed in Figure 1. Compared
with patients in whom angiographic success was achieved, the
probability of survival in patients in whom angiographic suc-
cess was not achieved was similar at 3 years after the procedure
(68% vs. 76%, respectively, p 0.69), as was freedom from the
combined endpoints of death and myocardial infarction (55%
vs. 66%, respectively, p  0.35) and death, myocardial infarc-
tion and recurrent severe angina (23% vs. 29%, respectively,
p  0.82). Freedom from repeat bypass surgery (65% vs. 51%,
respectively, p  0.05) was greater among patients in whom
angioplasty had been successful, although repeat coronary
angioplasty (67% vs. 91%, respectively, p  0.10) tended to be
more frequent among patients in whom angioplasty had been
successful in the 3 years after the procedure.
Repeat angiography during the follow-up period was per-
formed for clinical indications in 26 patients in whom angio-
graphic success had been achieved. The median time to
follow-up angiography was 9 months. Reocclusion had oc-
curred in 9 patients; restenosis had occurred in an additional
15. Therefore, restenosis or reocclusion occurred in 24 (92%)
of 26 patients undergoing repeat angiography and in at least 24
(44%) of 55 of patients in whom the procedure had initially
been successful. Repeat coronary angioplasty of the vein graft
was attempted in 14 patients, 3 of whom ultimately underwent
repeat bypass surgery. Four patients underwent repeat bypass
surgery without undergoing repeat coronary angioplasty.
Predictors of adverse events. Univariate analysis revealed
that the age of the vein graft (risk ratio [RR] 1.11, 95%
conﬁdence interval [CI] 1.00 to 1.23, p  0.05) and the use of
newer interventional devices in addition to balloon angioplasty
(RR 3.01, 95% CI 1.27 to 7.11, p  0.01) were associated with
the combined endpoint of death and myocardial infarction.
Failure to achieve angiographic success was not associated with
death and myocardial infarction in the 3 years after the
procedure (RR 1.50, 95% CI 0.63 to 3.54, p  0.37). Proce-
dural success was not associated with freedom from these
adverse events after adjusting for these other variables (RR
1.01, 95% CI 0.40 to 2.55, p  0.98).
Discussion
The most important ﬁndings of this study are that coronary
angioplasty of occluded vein grafts is associated with a low
success rate and a high complication rate and that even in
patients in whom angiographic success was achieved, adverse
cardiovascular events occur as frequently in the subsequent 3
years as in patients in whom angiographic success was not
achieved.
Although coronary artery bypass surgery has been shown
(12–16) to increase survival in certain subsets of patients and to
reduce symptoms of angina in others, the temporary duration
of the beneﬁt remains a problem. Five years after coronary
artery bypass surgery, 25% of vein grafts are occluded (1), and
50% of vein grafts are occluded at 10 years (1). Reoperation
in such patients is performed with increasing frequency. How-
ever, repeat bypass surgery is associated with an approximately
threefold greater risk of in-hospital death and myocardial
infarction than initial bypass surgery (3). In addition, repeat
bypass surgery is associated with less complete relief of angina
and reduced graft patency (17,18).
Accordingly, cardiologists have sought to develop percuta-
neous means of revascularization in such patients. Whenever
possible, the native coronary circulation is targeted for inter-
vention because of the greater success rate, lower complication
rate and lower restenosis rate than angioplasty of vein grafts
(19,20). When the native coronary circulation is not amenable
to percutaneous treatment, multiple approaches have been
used for the treatment of vein graft disease, including balloon
angioplasty (4,6–10,20), directional atherectomy (21), translu-
minal extraction catheter (22), excimer laser (23) coronary and
“biliary” stents (10,24–26) and prolonged infusions of throm-
bolytic therapy directly into the occluded graft (11). Only a
single randomized trial comparing any of these therapies with
balloon angioplasty has been reported (CAVEAT II [4]). The
results of CAVEAT II indicated that the frequency of
angiographic restenosis after balloon angioplasty of vein
grafts was similar to that after directional coronary atherec-
Table 2. Angiographic Outcome and Frequency of Adverse Events During 30 Days After Attempted
Angioplasty of an Occluded Vein Graft
Entire Study Cohort
(n  77)
Group 1
(n  55)
Group 2
(n  22) p Value
Complications 30 days
Death 4 (5.2) 2 (3.6) 2 (9.1) 0.33
Q wave MI 1 (1.3) 1 (1.8) 0 (0) 0.52
Bypass surgery 6 (7.8) 4 (7.2) 2 (9.1) 0.79
Within 24 h 2 (2.6) 1 (1.8) 1 (4.5) 0.63
Any of above 10 (13.0) 6 (10.9) 4 (18.2) 0.39
Distal embolization 9 (11.7) 7 (12.7) 2 (9.1) 0.98
Elevation of CK 16/37 (43) 11/23 (48) 5/14 (36) 0.54
Data presented are number (%) of patients. CK creatine kinase (measured in only 37 patients of the study cohort);
other abbreviations as in Table 1.
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tomy; patients with occluded vein grafts were not eligible for
the study (4). It should be emphasized that angioplasty of
occluded vein grafts is associated with an even lower success
rate, a higher complication rate and a higher restenosis rate
than angioplasty of vein grafts with subtotal stenoses; patients
with occluded vein grafts were not eligible for inclusion in
CAVEAT II (4).
In the present study, we performed a retrospective analysis
of patients undergoing percutaneous interventions in totally
occluded vein grafts. Although the 71% angiographic success
rate in these patients is similar to our previously reported 69%
angiographic success rate in patients undergoing angioplasty of
occluded coronary arteries (27), there was undoubtedly greater
selection bias in choosing which patients with occluded vein
grafts to treat. Occluded vein grafts are generally more difﬁcult
to restore anterograde ﬂow in than are occluded coronary
arteries because of the greater length of the occlusion and the
larger thrombus burden in occluded grafts. However, even in
the patients in the present study in whom angiographic success
was achieved, there was no apparent clinical beneﬁt in terms of
freedom from adverse cardiovascular events compared with
those in whom angiographic success could not be achieved.
This disappointing ﬁnding is probably due to a combination of
factors, including the occurrence of early complications in
patients despite angiographic success having been achieved; a
high restenosis and reocclusion rate in successfully treated
grafts; and progression of disease elsewhere in the treated
graft, in other grafts and in the native coronary circulation.
Adjunctive therapies to balloon angioplasty, used in 48% of
the procedures in the present study, may have inﬂuenced the
immediate and long-term outcome of our patients. Univariate
analysis suggested that their use was associated with an in-
Figure 1. Kaplan-Meier event-free survival curves comparing pa-
tients in whom angiographic success was achieved (n  55) with
those in whom angiographic success was not achieved (n  22).
Curves represent event-free survival in terms of freedom from
death (A); death and myocardial infarction (MI) (B); and death,
myocardial infarction and severe angina (C). Freedom from repeat
coronary artery bypass surgery (CABG) (D) and repeat percuta-
neous transluminal coronary angioplasty (PTCA) (E) are also
shown.
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creased occurrence of death and myocardial infarction in the 3
years after the procedure. This ﬁnding may be the result of
selection bias; more difﬁcult cases may have been attempted
with these newer devices than would have been attempted with
balloon angioplasty alone. Whether the use of newer devices
inﬂuences the success, complication and restenosis rates asso-
ciated with angioplasty of occluded vein grafts will require
randomized trials to be determined. Evidence from other
studies indicating beneﬁt from use of stents in vein grafts with
subtotal stenoses argues for the inclusion of a percutaneous
intervention arm in future randomized trials comparing bypass
surgery with medical therapy in the treatment of patients with
vein graft disease (10,24–26). However, whether stents will be
as effective in vein grafts ﬁlled with thrombus and atheroscle-
rotic debris is unclear.
Limitations of the study. The occluded grafts in the
present study generally contained an enormous thrombus
burden, and many revealed persistent thrombus even after the
procedure was successful and Thrombolysis in Myocardial
Infarction (TIMI) grade 3 ﬂow was restored. Current practice
would be to place stents in vein graft stenoses if, after
predilation, signiﬁcant thrombus was no longer apparent.
Although this was not the case with the majority of vein grafts
in this series, it is likely that at least some of the patients in this
study would have received stents if their procedure were
performed today, and the infrequent use of stents may have
affected the poor outcome of patients in the study. Random-
ized trials comparing balloon angioplasty with stents in the
treatment of stenotic vein grafts are ongoing, although patients
with occluded vein grafts are excluded from these trials. The
retrospective nature of the present study and the small num-
bers of patients treated with stents, other new interventional
devices and thrombolytic therapy preclude a determination of
whether and to what extent each of these therapies inﬂuenced
the immediate and long-term outcome of patients in this study.
Although in patients with a recent myocardial infarction the
vein graft that was treated was believed to have been the
infarct-related vessel, this could not be determined with cer-
tainty. The duration of the occlusion in patients without a
recent infarction could not be determined in many cases.
Conclusions. Angioplasty of occluded vein grafts is associ-
ated with a low initial success rate and a high complication
rate, whether or not a recent myocardial infarction has oc-
curred. Successful angioplasty does not appear to reduce the
occurrence of adverse events in the 3 years after the procedure.
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